Litigation Details for Alexion Pharmaceuticals, Inc. v. Samsung Bioepis Co. Ltd. (Fed. Cir. 2024)

✉ Email this page to a colleague

Docket	⤷ Sign Up	Date Filed	2024-05-20
Court	Court of Appeals for the Federal Circuit	Date Terminated	2024-09-04
Cause		Assigned To
Jury Demand		Referred To
Patents	9,447,176; 9,718,880; 9,732,149
Link to Docket	External link to docket

The biologic drug covered by the patents cited in this case is ⤷ Sign Up .

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2024-06-21	13		10,590,189 (“the ’189 patent”), 10,703,809 (“the ’809 patent”), and 9,447,176 (“the ’176 patent”). The SOLIRIS…Complaint (D.I. 1) Exhibit 4 U.S. Patent No. 9,447,176 Exhibit 5 U.S. Patent No. 10,590,189 Exhibit 6 Notice…following six patents: Nos. 9,732,149 (“the ’149 patent”), 9,718,880 (“the ’880 patent”), 9,725,504 (…claims: claim 1 of the ’176 patent (Ex. 4) and claim 1 of the ’189 patent (Ex. 5) (collectively, the “… Amgen filed IPRs against the parent patents of the ’189 patent. After Amgen filed its IPRs, the entire	External link to document
2024-07-01	15		United States Patent Nos. 9,447,176 (the “’176 patent”) and 10,590,189 (the “’189 patent”) (collectively…hemoglobinuria (“PNH”), and claim 1 of U.S. Patent No. 9,447,176 (“the ’176 patent”) recites a method of treating …, 2024; United States Patent No. 9,447,176; and United States Patent No. 10,590,189. 11 … 29 United States Patent No. 9,447,176. 30 United States Patent No. 10,590,189. 31 …10,590,189. 2. United States Patent No. 9,447,176. 3. United States Patent No. 9,732,149 B2. Depositions	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document